News

NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation

Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. Additionally, the parties will collaborate to discover and validate new targets that play

The claims in the patent cover, among other inventions, Acura’s IMPEDE Technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine. This

XGEVA was approved and granted Orphan Drug Designation by the FDA, which is reserved for drugs that are intended for the treatment of rare diseases affecting fewer than

Under the terms of the agreement, Biopharm will market NeutroPhase in Egypt, Saudi Arabia, Algeria, Sudan and Libya. Saudi Arabia, in particular, is a large potential market for

The three parties will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Under the deal, each company will bring

Both the firms will jointly work on a worldwide basis with the aim of bringing an important investigational therapy to patients. Pfizer senior vice president and chief scientific

PXVX0200 uses the same attenuated vaccine strain (CVD 103-HgR) previously approved and marketed in several countries under the brand name Orochol. The company plans to submit a Biologics

The trial is designed to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with Merck’s Keytruda, the first anti-PD-1 (programmed death receptor-1) therapy